Neurology Journal
Fecha de publicación: 15 March 2019
DOI: https://doi.org/10.1212/WNL.0000000000007271
Autores: Rachel Gurrell, Donal Gorman, Mark Whitlock, Adam Ogden, David S. Reynolds, Bree DiVentura, Bassel Abou-Khalil, Michael Gelfand, John Pollard, et al.
Background: The objective of this phase 2a study was to assess the activity of PF-06372865, a positive allosteric modulator (PAM) of α2/3/5 subunit-containing GABAA receptors with minimal activity at α1-containing receptors, which are believed to mediate many of the adverse events associated with benzodiazepines, in the epilepsy photosensitivity model as a proof-of-principle of efficacy.
